Lactobacillus casei PXN 37

What does the research say about Lactobacillus casei PXN 37?

2 health outcomes synthesised

Research on Lactobacillus casei PXN 37 has examined two health outcomes: reduced inflammation and improved quality of life. The strongest evidence supports a moderate effect on reducing inflammation, based on 3 studies (including a meta-analysis of 703 patients with autoimmune diseases), though the effect may be limited to certain subgroups. No consistent effective dose has been identified across the available research.

Strongest evidence The most researched outcome for Lactobacillus casei PXN 37 is reduced inflammation, with a moderate evidence strength. All 3 studies reported beneficial effects, and 2 of 3 showed statistically significant results. A meta-analysis in patients with autoimmune diseases (n=703) found moderate reductions in IL-6, TNFα, and hs-CRP. One study reported a small effect only in depressed patients with somatic comorbidities. No dose range or study duration was consistently reported.

Mixed or weaker evidence Evidence for improved quality of life is rated low, because no primary study isolated Lactobacillus casei PXN 37; all analyses used synbiotic or multi-strain formulations, making it impossible to attribute effects solely to this strain. The 3 reviews (covering CRC, neurodegenerative diseases, and GI patients) all reported beneficial effects with small-to-moderate effect sizes, but none reported statistically significant findings for this specific substance-outcome pair.

Effective dose patterns No effective dose could be determined for either outcome. Across all studies, dose ranges and study durations were either not reported or not consistently described, precluding any dose-response conclusions.

Population insights Two patient groups appear most studied: patients with autoimmune diseases (for inflammation) and patients with colorectal cancer, neurodegenerative diseases, or gastrointestinal disorders (for quality of life). The anti-inflammatory effect may be strongest in autoimmune populations, while one study suggests a possible subgroup effect in depressed patients with somatic comorbidities.

Notable caveats

Two of the three inflammation studies are meta-analyses with overlapping populations, potentially inflating consistency.
For quality of life, no primary study isolates this single strain—all data come from synbiotic or multi-strain formulations.
Doses and study durations are rarely reported, limiting practical interpretation.
Sample sizes were not available for most quality-of-life studies.

Frequently asked

What is Lactobacillus casei PXN 37 good for according to research?
Research on Lactobacillus casei PXN 37 has focused on two outcomes: reduced inflammation (moderate evidence, 3 studies) and improved quality of life (low evidence, 3 studies). For inflammation, 2 of 3 studies showed statistically significant benefits, particularly in patients with autoimmune diseases.
What dose of Lactobacillus casei PXN 37 is typically used in studies?
No consistent effective dose has been identified. Doses and study durations were not consistently reported across the available studies, making it impossible to determine a typical or effective dose range for either inflammation or quality of life.
Who benefits most from Lactobacillus casei PXN 37?
The strongest evidence points to patients with autoimmune diseases, where a meta-analysis of 703 individuals showed moderate reductions in inflammatory markers. One study also suggested a small effect in depressed patients with somatic comorbidities. For quality of life, evidence is too weak to identify specific subgroups that benefit.
Are there caveats or limitations in the research on Lactobacillus casei PXN 37?
Yes. For inflammation, the two meta-analyses have overlapping populations, which may inflate consistency, and one study found an effect only in a subgroup. For quality of life, no study isolated this single strain—all used synbiotic or multi-strain formulations, making it impossible to attribute effects solely to Lactobacillus casei PXN 37. Doses and study durations were often unreported.
Does Lactobacillus casei PXN 37 help reduce inflammation?
The evidence is moderate. All 3 studies reported beneficial effects, with 2 showing statistically significant reductions in IL-6, TNFα, and hs-CRP, especially in patients with autoimmune diseases. However, one study found only a small effect limited to a subgroup of depressed patients with somatic comorbidities.
Does Lactobacillus casei PXN 37 improve quality of life?
Evidence is low. Three reviews reported beneficial effects (small to moderate) in patients with colorectal cancer, neurodegenerative diseases, and GI disorders, but none of the results were statistically significant for this specific strain. Because all studies used multi-strain or synbiotic products, the effect cannot be attributed to Lactobacillus casei PXN 37 alone.

Most-studied combinations with Lactobacillus casei PXN 37

most supplement research is combination research

Also studied with:Lactobacillus rhamnosus PXN 54 (6), Streptococcus thermophilus PXN 66 (8)